Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

October 25, 2023

Study Completion Date

December 30, 2023

Conditions
C-Met Exon 14 Mutation
Interventions
DRUG

Glumetinib

The investigational product will be orally administrated when fasting at dose level of 300mg QD

Trial Locations (44)

40233

NOT_YET_RECRUITING

Norton Cancer Institute, Louisville

RECRUITING

The Oncology Institute of Hope & Innovation, Louisville

100000

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Beijing Cancer Hospita, Beijing

RECRUITING

Peking Union Medical College Hospital, Beijing

110000

RECRUITING

Liaoning Cancer Hospital, Shenyang

130000

RECRUITING

First Hospital of Jilin University, Changchun

150000

RECRUITING

Cancer Hospital Affiliated to Harbin Medical University, Harbin

200000

RECRUITING

Changhai Hospital, Shanghai

RECRUITING

Fudan university Shanghai cancer center, Shanghai

RECRUITING

The Chest Hospital of Shanghai, Shanghai

210000

RECRUITING

Jiangsu Cancer Hospital, Nanjing

RECRUITING

Jiangsu Province People's Hospital, Nanjing

230000

RECRUITING

Anhui Province Hospital, Hefei

RECRUITING

The Chest Hospital of Anhui Province, Hefei

250000

RECRUITING

Shandong University Qilu Hospital, Jinan

300000

RECRUITING

Tianjin Cancer Hospital, Tianjin

RECRUITING

Tianjin Medical University General Hospital, Tianjin

310000

RECRUITING

The First Affiliated Hospital,College of of Medicine, Zhejiang University, Hangzhou

RECRUITING

Zhejiang Province Cancer Hospital, Hangzhou

330000

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

350000

RECRUITING

Union Medical College Hospital Affiliated to Fujian Medical University, Fuzhou

410000

RECRUITING

Xiangya Hospital Central South University, Changsha

RECRUITING

Hunan Province Cancer Hospital, Changsha

430000

RECRUITING

Hubei Cancer Hospital, Wuhan

RECRUITING

Wuhan Union Hospital, Wuhan

450000

RECRUITING

Henan Province Cancer Hospital, Zhengzhou

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510000

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

530000

RECRUITING

Cancer Hospital Affiliated to Guangxi Medical University, Nanning

570000

RECRUITING

Hainan Cancer Hospital, Haikou

610000

RECRUITING

West China Hospital of Sichuan University, Chengdu

071000

RECRUITING

Affiliated Hospital of Hebei University, Baoding

Unknown

RECRUITING

Ehime University Hospital, Ehime

RECRUITING

Kyushu University Hospital, Fukuoka

RECRUITING

Kanagawa Cancer Center, Kanagawa

RECRUITING

Niigata Cancer Center Hospital, Niigata

RECRUITING

Kindai University Hospital, Osaka

RECRUITING

Osaka International Cancer Institute, Osaka

RECRUITING

Hokkaido University Hospital, Sapporo

RECRUITING

Shizuoka Cancer Center, Shizuoka

RECRUITING

National Cancer Center Hospital East, Tokyo

RECRUITING

National Cancer center, Tokyo

RECRUITING

Tottori University Hospital, Tottori

Sponsors
All Listed Sponsors
lead

Haihe Biopharma Co., Ltd.

INDUSTRY